目的 觀察重組人生長(zhǎng)激素治療敗血癥患兒的臨床療效及對(duì)肌酸激酶同工酶(CK-MB)、肌酸磷酸激酶(CK)和血清炎癥因子的影響。方法 2011年2月-2014年5月武警河北總隊(duì)醫(yī)院收治的敗血癥患兒80例,隨機(jī)分為對(duì)照組和治療組,每組40例。對(duì)照組給予綜合治療,同時(shí)給予抗生素治療。治療組患者入院第2天腹部sc注射用重組人生長(zhǎng)激素,0.1 U/kg,隔日1次,其他治療同對(duì)照組。兩組均連續(xù)治療10 d。比較兩組的臨床療效,同時(shí)比較兩組治療前后CK-MB、CPK、中性粒細(xì)胞凝膠酶載脂蛋白(NGAL)、腫瘤壞死因子-α(TNF-α)以及胰島素樣生長(zhǎng)因子-1(IGF-1)的變化。結(jié)果 對(duì)照組和治療組總有效率分別為77.5%、90.0%,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,兩組CK、CK-MB、NGAL、TNF-α、IGF-1水平均較治療前明顯下降,同組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05);且治療組的改善程度優(yōu)于對(duì)照組,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 重組人生長(zhǎng)激素治療新生兒敗血癥有較好的臨床療效,可降低患兒心肌損傷,減輕全身炎癥反應(yīng)。

Objective To investigate the efficacy of recombinant human growth hormone (rhGH) in treatment of neonatal sepsis, the influences of recombinant human growth hormone about CK-MB, CK, and serum inflammatory factors. Methods Children (80 cases) with neonatal sepsis who came to the Armed Police Hebei Corps Hospital from February 2011 to May 2014 were randomly divided into the control and treatment groups, and each group had 40 cases. The patients in control group were given comprehensive treatment, and at the same time they were iv administered with corresponding antibiotics. The patients in treatment group were sc administered with Recombinant Human Growth Hormone for injection every other day, 0.1 U/kg, and other treatment was the same as the control group. The patients in the two groups were treated for 10 d. After the treatment, the efficacy was evaluated, at the same time the changes of CK-MB, CK, NGAL, TNF-α, and IGF-1 in two groups were compared. Results The efficacies in the control and treatment groups were 77.5% and 90.0%, respectively, and there were differences between two groups (P< 0.05). After treatment, the levels of CK, CK-MB, NGAL, TNF-α, and IGF-1in two groups were significantly decreased, and the difference was statistically significant in the same group (P< 0.05). And the improvement degree of the treatment group was better than that in the control group, with significant differences between two groups (P< 0.05). Conclusion Recombinant human growth hormone has the good clinical effect in treatment of neonatal sepsis, and can reduce myocardial injury, which can relieve systemic inflammatory response.

河北省衛(wèi)生廳科研基金項(xiàng)目(20110569)